Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
223 hedge funds and large institutions have $3.13B invested in Global Blood Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 93 increasing their positions, 47 reducing their positions, and 27 closing their positions.
98% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 47
89% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 27
11% more funds holding
Funds holding: 201 → 223 (+22)
2% more capital invested
Capital invested by funds: $3.07B → $3.13B (+$59.2M)
1% less call options, than puts
Call options by funds: $72.6M | Put options by funds: $73.3M
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$40.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.9M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$25.1M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$22.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$95.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$62.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$28.3M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$21.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$11.9M |
GBT Hedge Fund Activity: Q2 2019 in Review
223 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2019, worth a combined $3.13B — up 1.9% from $3.07B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new GBT positions and 27 closed out — a net gain of 24 holders — while 93 added to existing stakes and 47 trimmed.
The largest buyer was Franklin Resources, adding an estimated $40.5M. The largest seller was Camber Capital Management, exiting entirely with an estimated $95.3M sold.
- 223 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2019, up from 201 in Q1 2019.
- Funds reported $3.13B of Global Blood Therapeutics, Inc. stock for Q2 2019, up 1.9% quarter-over-quarter.
- 51 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2019 and 27 closed out, a net change of +24 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q2 2019 was Franklin Resources, an estimated $40.5M added.
- The largest Global Blood Therapeutics, Inc. seller in Q2 2019 was Camber Capital Management, an estimated $95.3M sold.
Based on aggregated 13F filings for Q2 2019.